KEIO RESEARCHERS INFORMATION SYSTEM

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（医学）, 慶應義塾大学

Books 【 Display / hide 】

Books 【 Display / hide 】

• Stem cell research for the treatment of malignant glioma.

  Tamura R and Toda M, Brain Tumor, InTech, Croatia, 2017

• Glioma Antigen Glioma: Immunotherapeutic approaches

  Toda M, R Yamanaka (Ed.), In Landes Bioscience, 2012

• Brain tumor stem cells and anti-angiogenetic therapy

  Saito K, Yoshida K, Toda M, Cancer Stem Cells, The Cutting　Edge Stanley Shostak (Ed.), InTech, Croatia, 2011

  Contact page： 229-246

• Immunotherapy targeted at brain cancer stem cells

  Toda M, Brain Tumor Immunotherapy, The Open Cancer Immunology Journal Terry Lichtor (Ed.), Bentham open,, 2010

  Contact page： 48-50

• Treatment of metastatic brain tumors with a replication-competent multi-mutated herpes simplex virus-1.

  Toda M, Uyemura K, Kawase T, Rabkin SD, Martuza RL, Neural Development, Springer-Verlag, 1999

  Contact page： 521-525

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Imaging of the venous plexus of Rektorzik using CT-digital subtraction venography:a retrospective study

  Ryota Imai,Katsuhiro Mizutani,Takenori Akiyama,Takashi Horiguchi,Yoshifumi Takatsume,Masahiro Toda

  Neuroradiology （Spriger)  online 2022.04

  Research paper (scientific journal), Joint Work

• Surgical Planning and Simulation of Endonasal Endoscopic Surgery for Pituitary Adenoma with Cavenous Sinus Invasion

  Tamura R,Oda H,Kosugi K,Toda M

  Operative　Neurosurgery （journal)   2022

  Joint Work, Corresponding author, Accepted

• Cone-beam computed tomography fusion technique for vascular assessment of skull base meningiomas

  Yoshida K, Akiyama T, Takahashi S, Miwa T, Horiguchi T, Sasaki H, Toda M

  World Neurosurg S1878-8750 （ 21 ）  2021.04

  Research paper (scientific journal), Joint Work

  • Access to Document (DOI)

• A novel histopathological classification of meningiomas based on dural invasion

  Murase M, Tamura R, Kuranari Y, Sato M, Ohara K, Morimoto Y, Yoshida K, Toda M

  J Clin Path 74 （ 4 ） 238 - 243 2021.04

  Research paper (scientific journal), Joint Work, Accepted

  　View Summary

  Aims Histological invasion into the adjacent brain parenchyma is frequently investigated in meningioma because it is an important morphological criterion for grade II meningioma according to the 2016 WHO classification. However, few studies have focused on dural invasion of meningiomas. Herein, we propose a novel histopathological classification based on dural invasion of meningiomas. Methods Forty-nine cases with WHO grade I meningiomas who underwent Simpson grade I removal were collected. After the meningeal layer (ML) and periosteal layer (PL) of dura mater were visualised by Masson's trichrome stain, we evaluated the depth (to the ML and PL) and the patterns (1, expanding; 2, infiltrating) of dural invasion of meningiomas using serial paraffin sections. Invasion-associated markers, including Ki-67, matrix metalloproteinase (MMP)-1, MMP-9 and MMP-13, aquaporin 1 and Na-K-2Cl cotransporter, were quantitatively analysed by immunohistochemistry. Results Thirty-five cases (71.4%) showed the dural invasion. In 27 of these 35 cases (77.1%), dural invasion was localised in ML. Type 1 (expanding type) and type 2 (infiltrating type) invasions were observed in 23 and 12 cases, respectively. The recurrence rate in cases with type 2 invasion was significantly higher than that in cases with type 1 invasion. The percentage of MMP-1-positive tumour cells was also significantly higher in cases with dural invasion than those without, suggesting involvement of MMP-1 in dural invasion. Conclusions We quantitatively evaluated the depth and patterns of dural invasion in meningiomas. The patterns of dural invasion were associated with meningioma recurrence.

  • Access to Document (DOI)

• Angio-anatomical study of the pterygovaginal artery based on cone-beam computed tomography

  Yoshida K, Akiyama T, Raz E, Kamamoto D, Ozawa H, Toda M

  Neruoradiology （Neuroradiology)   2021.02

  Research paper (scientific journal), Joint Work, Accepted,  ISSN  00283940

  　View Summary

  Purpose: To investigate the anatomical characteristics and clinical implications of the pterygovaginal artery (PtVA), a recurrent branch from the distal internal maxillary artery (IMA), which courses through the pterygovaginal canal that connects the pterygopalatine fossa and nasopharynx. Methods: Eighty-two patients with 90 sides of cone-beam computed tomography (CBCT) reconstructed from rotational angiography of the external or common carotid artery with a field of view covering the pterygopalatine fossa were retrospectively reviewed. The origin from the IMA, branching type, distribution, and anastomoses was evaluated. The underlying lesions were 36 hypervascular lesions with possible supply from PtVA (17 cavernous sinus arteriovenous fistulas (AVFs), 6 anterior condylar AVFs, and 13 nasopharyngeal, parasellar, or paraclival tumors) and 46 other diseases. Results: PtVA was identified in 75 sides (83%). It originated from the pterygopalatine segment of the IMA in 45 sides (60%) and from the pterygoid segment in 30 sides (40%). It arose independently (77%), sharing the common trunk with the Vidian artery (15%) or with other branches. It ran posteromedially through the pterygovaginal canal to supply the mucosa over the nasopharyngeal roof, the choanae, and the pharyngeal ostium of the eustachian tube. It anastomosed with the ascending pharyngeal artery (n=37), the accessory meningeal artery (n=7), and the mandibular artery from the petrous internal carotid artery (n=2). It served as a feeder of osseous AVFs and skull base tumors. Conclusion: PtVA was often identified by CBCT even in normal anatomy. Its detailed angio-anatomy could be evaluated in the presence of parasellar or paraclival hypervascular lesions.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of novel vaccine immunotherapy for malignant glioma

  Toda, Masahiro

  科学研究費補助金研究成果報告書 2019

• Investigation of immunovirotherapy for malignant brain tumors using neural stem cells and oncolytic viruses

  Toda, Masahiro

  科学研究費補助金研究成果報告書 2018

• Gene-cell therapy using iPS cells for the treatment of brain tumor

  Toda, Masahiro

  科学研究費補助金研究成果報告書 2017

• Biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines against malignant glioma patients

  Toda, Masahiro

  科学研究費補助金研究成果報告書 2017

• Cell therapy by human iPSC-transplantation for functional repair of stroke-damaged neural circuitry and malignant brain tumor

  Toda, Masahiro

  科学研究費補助金研究成果報告書 2016

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

  Tamura R., Fujioka M., Morimoto Y., Ohara K., Kosugi K., Oishi Y., Sato M., Ueda R., Fujiwara H., Hikichi T., Noji S., Oishi N., Ogawa K., Kawakami Y., Ohira T., Yoshida K., Toda M.

  Nature Communications (Nature Communications)  11 ( 1 )  2020.12

  　View Summary

  The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

  • Access to Document (DOI)

• Erratum: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma-a case series (BMC Cancer (2020) 20 (196) DOI: 10.1186/s12885-020-6589-x)

  Tamura R., Morimoto Y., Kosugi K., Sato M., Oishi Y., Ueda R., Kikuchi R., Nagashima H., Hikichi T., Noji S., Kawakami Y., Sasaki H., Yoshida K., Toda M.

  BMC Cancer (BMC Cancer)  20 ( 1 )  2020.04

  　View Summary

  Following publication of the original article [1], the authors reported an error in the author group. It was reported that Tetsuro Hikichi was missing and the corrected author group is as follows: Ryota Tamura1, Yukina Morimoto1, Kenzo Kosugi1, Mizuto Sato1, Yumiko Oishi1, Ryo Ueda1, Ryogo Kikuchi2, Hideaki Nagashima1, Tetsuro Hikichi4, Shinobu Noji3, Yutaka Kawakami3, Hikaru Sasaki1, Kazunari Yoshida1 and Masahiro Toda1*The competing interests statement has been updated to: TH is an employee of OncoTherapy Science, Inc. The original article [1] has been corrected.

  • Access to Document (DOI)

• In Reply to the Letter to the Editor Regarding “Treatment Strategy for Tuberculum Sellae Meningiomas Based on Preoperative Radiologic Assessment”

  Kuga D., Toda M., Yoshida K.

  World Neurosurgery (World Neurosurgery)  125 2019.05

  ISSN  18788750

  • Access to Document (DOI)

• Current Understanding of Lymphatic Vessels in the Central Nervous System

  Tamura R, Yoshida K, Toda M.

  Neurosurg Rev　  2019

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Access to Document (DOI)

• Recent progress in the research of suicide gene therapy for malignant glioma.

  Tamura R, Miyoshi H, Yoshida K, Okano H, Toda M

  Neurosurg Rev  2019

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Access to Document (DOI)

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 良性脳腫瘍：開頭術と内視鏡手術の協調

  戸田正博

  第42回日本脳神経外科コングレス総会 (大阪) , 

  2022.05

  , 

  Oral presentation (invited, special), 熊本大学

• 難治性脳腫瘍の手術と新たな治療法の開発

  戸田正博

  2022 Neurosurgery meeting in Nagoya (名古屋) , 

  2022.04

  , 

  Oral presentation (invited, special), バクスター株式会社

• 頭蓋底疾患に対する内視鏡手術と新たな治療法の開発

  戸田正博

  (オンライン) , 

  2022.04

  , 

  Oral presentation (invited, special), Skill-building Neurosurgical Conference

• iPS細胞由来神経前駆細胞を用いた脳腫瘍に対するex vivo遺伝子治療

  戸田正博

  (オンライン) , 

  2022.03

  , 

  Oral presentation (invited, special)

• Suicide gene therapy using genome-edited iPS cells against malignant glioma

  戸田正博

  (日本橋) , 

  2022.01

  , 

  Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 悪性脳腫瘍に対するウイルス搭載iPS細胞を用いた新規治療の開発

  2021.04

  -

  2024.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

• 複製制御型ウイルスを搭載した神経幹細胞による脳腫瘍治療法

  2020.04

  -

  2021.03

  AMED, 橋渡し研究戦略的推進プログラム, Research grant, Principal investigator

  　View Summary

  本年度は、抗腫瘍効果と安全性をさらに高める新retroviral replicating vector (RRV)の開発に努めた。
  まず、自殺遺伝子yeast cytosine deaminase (yCD)の抗腫瘍効果を高めるuracil phosphoribosyl transferase (UPRT)（5-Fluorouracil [5-FU] を5-fluorouridine monophosphate [5-FUMP] へ変換することにより、yCD単独と比べ 100倍以上の細胞死誘導効率が得られる）に着目した。実際にグリオーマに対する抗腫瘍効果もyCD単独よりyCD/UPRTが優れていることを、あらかじめ予備実験で明らかにしており、RRVにyCDとUPRTを組み込むことを試みた。一方、UPRTは長配列であり、RRVが約1.5kb程度の配列長しか搭載できないため、この検討にやや時間を要した。最終的には、Envの下流にIRES-yCDを繋げるのではなく、2A-yCD/UPRTに変更することでyCD/UPRTの安定発現が可能となった。比較対象として、CAG-yCDも安定発現を確認できたため、これらRRVの抗腫瘍効果をin vitroで比較検討した。U87に各RRVをmoi-0.1で感染させ2週間培養後に5-FCを投与し、その1週間後にCCK-8 assayでLD50値を測定したところ、RRV-2A-yCD/UPRTの抗腫瘍効果が最も高いことが明らかになった。同様にGSC細胞株hG008に対しても、顕著な優位性を示すことに成功した。さらに、RRV-2A-yCD/UPRTがiPS-NSCに感染し複製可能であることを確認した。

• ゲノム編集iPS細胞による遊走性を利用した悪性神経膠腫に対する遺伝子細胞療法の研究開発

  2019.04

  -

  2024.03

  AMED, 先端的バイオ創薬等基盤技術開発事業, Research grant, Principal investigator

• 遺伝性疾患・神経線維腫症２型に対する革新的治療法（新規免疫療法）の開発

  2019.04

  -

  2021.03

  橋渡し研究戦略的推進プログラム・シーズB, No Setting

• 自殺遺伝子CD-UPRTゲノム編集iPS細胞を用いた遺伝子治療

  2018.06

  -

  2021.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory) , Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• THERAPEUTIC AGENT USING GENOME-EDITED PLURIPOTENT STEM CELL

  Date applied： 2020-063477  2021.03 

  Date announced： WO 2021/201100 A1  2021.10 

  Patent

• 脳腫瘍幹細胞を用いた治療薬スクリーニング法

  Date applied： 特願2019-052704  2019.03 

  Patent, Joint

• 脳腫瘍治療用細胞製剤

  Date applied： 特願2019－517657  2018.05 

  Date issued： 特許第7051060 

  Date registered： 2022.04

  Patent

• 多能性幹細胞を用いた自殺遺伝子脳腫瘍治療薬

  Date applied： 特願２０１７－２２３２０２  2017.11 

  Patent, Joint

• 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物

  Date applied： 特願２０１７－１００３６１  2017.05 

  Patent, Single

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• SURGERY

  2022

• NEUROSURGERY: SEMINAR

  2022

• NEUROSURGERY: PRACTICE

  2022

• NEUROSURGERY

  2022

• LECTURE SERIES, NEUROSURGERY

  2022

display all >>

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• Surgical simulation in Neurosurgery

  Keio University

  2015.04

  -

  2016.03

• pituitary tumor

  Keio University

  2015.04

  -

  2016.03

  , 

  Lecture

• Topics in Neurosurgery

  Keio University

  2015.04

  -

  2016.03

  , 

  Full academic year, Lecture

Media Coverage 【 Display / hide 】

Media Coverage 【 Display / hide 】

• iPSとゲノム編集で脳腫瘍治療

  株式会社朝日新聞社, 朝日新聞社 （科学) , 2022.04

• 慶應大戸田氏、脳腫瘍にiPS細胞由来神経幹細胞を用いたex vivoの遺伝子治療を開発中

  株式会社 日経BP, 日経バイオテクONLINE, 2022.03